FTSE 100 movers: GSK surges on Zantac deal; Taylor Wimpey goes ex-div
FTSE 100 (UKX) 8,245.01 0.02%
Shares in GSK surged after the pharmaceuticals company announced a $2.2bn settlement to resolve approximately 80,000 Zantac lawsuits in the US.
The company revealed that it had reached agreements with 10 firms, representing 93% of the state court product liability cases related to the drug.
Additionally, GSK agreed to pay $70m to resolve a whistleblower complaint filed by Valisure, which alleged that the firm had concealed the cancer risks of Zantac.
Insurers Beazley and Hiscox both gained as Hurricane Milton lessened in intensity before striking the US state of Florida.
Taylor Wimpey, Kingfisher, Tesco, and WPP all fell after trading ex-dividend.
FTSE 100 - Risers
GSK (GSK) 1,536.00p 5.35%
Beazley (BEZ) 775.50p 2.85%
Hiscox Limited (DI) (HSX) 1,130.00p 1.99%
Next (NXT) 10,005.00p 1.43%
Coca-Cola HBC AG (CDI) (CCH) 2,766.00p 1.32%
Fresnillo (FRES) 640.00p 1.27%
Aviva (AV.) 481.50p 0.86%
Haleon (HLN) 382.50p 0.84%
NATWEST GROUP (NWG) 352.70p 0.83%
United Utilities Group (UU.) 1,028.50p 0.78%
FTSE 100 - Fallers
Taylor Wimpey (TW.) 152.15p -4.82%
Vistry Group (VTY) 902.50p -4.45%
BAE Systems (BA.) 1,261.00p -3.22%
Whitbread (WTB) 3,074.00p -3.18%
Ashtead Group (AHT) 5,708.00p -2.43%
WPP (WPP) 760.20p -2.24%
Mondi (MNDI) 1,429.00p -2.12%
Barratt Redrow (BTRW) 453.40p -2.07%
Intertek Group (ITRK) 5,030.00p -2.04%
Persimmon (PSN) 1,572.00p -1.69%
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.